Developer docs
API playgroundTry for free, no card

Search company profiles

Ingenza

Full company profile

uuid00028xg

Namestring
Ingenza
Legal namestring
Ingenza Limited
Websiteurl
ingenza.com
Company typeenum
Private
Founded yearint
2003
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, strain engineering services, protein therapeutics development, biocatalysis small molecules, sustainable bioprocess development
Industry4 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Research Development and Manufacturing (CRDMO)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research and Manufacturing Services
TypeProfessional Services
Description

As a CRDMO, Ingenza provides fee-for-service preclinical and process development services through to first-in-human manufacturing. Revenue is generated through project-based contracts with pharmaceutical and biotech companies requiring protein production, strain development, and bioprocess optimization.

contractpharma.com
2Technology Licensing
TypeLicensing Royalties
Description

Ingenza licenses its proprietary technologies (such as inABLE®) to third parties. Syngenta has exercised commercial licensing options for enabling technologies developed by Ingenza.

ingenza.com
3Technology License Income (Bioethanol)
TypeLicensing Royalties
Description

Innovate UK grant funding supports commercialization of production technology targeting the bioethanol yeast market, with potential to generate substantial technology license income.

ingenza.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Project-based custom engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Services are tailored to customer requirements with bespoke project scopes. No standardized pricing tiers are published. Contact-based quoting process for strain development, process development, analytical services, and manufacturing.

contractpharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1inGenius®
Description

Proprietary chemistry manufacturing and controls (CMC) platform that accelerates and de-risks progression of novel drug candidates from strain/cell line development through to first-in-human trials.

ingenza.com
+3 more records
Core offering1 text field

Ingenza is a full-service protein Contract Research, Development and Manufacturing Organization (CRDMO) providing strain/cell line engineering, fermentation, process development, analytical development, and cGMP-ready material manufacturing for biologics, small molecule pharmaceuticals, and sustainable biotech applications. The company combines proprietary AI/ML tools (codABLE™) and its inGenius® CMC platform with multidisciplinary human expertise to deliver protein therapeutics and biocatalytic processes from discovery through first-in-human trials. It also licenses enabling technologies such as inABLE® to third parties and operates a multi-host production platform spanning E. coli, Bacillus subtilis, Pichia pastoris, and CHO cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100% success rate producing customer targets
+5 more records
Product overview1 text field

Ingenza operates as a protein Contract Research, Development and Manufacturing Organization (CRDMO) with a platform-plus-services architecture. The core inGenius® technology platform is enhanced by specialized AI/ML capabilities (codABLE™ for gene design optimization) and proprietary tools (inABLE® for DNA recombination). The service portfolio spans three main divisions—Biologics, Small Molecule, and Sustainable Biotech—each offering strain/cell line development, process development, analytical development, and material manufacturing. Specialized offerings include GenXpress Bacillus (an orthogonal protein production system), the inGenius® CMC platform for drug development, and diagnostic products like ester-impregnated pH strips. The company serves Human and Animal Health and Sustainable Technologies markets, combining AI tools with human expertise through a dual-engineering approach.

Product and service7 records
1Biologics CRDMO Services
CategoryBiologics CRDMO Services
Description

Full-service biologics development including strain/cell line engineering, process development, analytical development, and cGMP material manufacturing, supporting drug discovery through preclinical evaluation and first-in-human studies for pharmaceutical and biotech clients.

2Small Molecule CRDMO Services
CategorySmall Molecule CRDMO Services
Description

Engineering of efficient microbial production of natural products and biocatalytic regio- and enantio-selective synthesis of small molecule pharmaceuticals, chiral synthons, and advanced intermediates for pharmaceutical and chemical clients.

3Sustainable Biotech CRDMO Services
CategorySustainable Biotech CRDMO Services
Description

Deployment of sustainable bioprocesses for chemicals, enzymes, and custom solutions using diverse host organisms to achieve industrial performance, cost competitiveness, and Net Zero objectives for chemical, biofuel, and industrial biotech clients.

4codABLE™ AI/ML Gene Design Platform
CategoryAI/ML Bioprocess Technology
Description

AI/ML-driven gene design platform that uses machine learning to predict and tune recombinant protein expression by analyzing codon usage patterns, achieving predictive gene design for maximized production yields across E. coli, Bacillus subtilis, Pichia pastoris, and CHO hosts.

5GenXpress Bacillus Protein Production System
CategoryBiologics Production Platform
Description

Orthogonal protein production system using engineered Bacillus host, providing performance comparable to E. coli expression systems and serving as a highly productive alternative for endotoxin-free biologics manufacturing.

6inGenius® CMC Platform
CategoryCMC Development Platform
Description

Chemistry Manufacturing and Controls platform that accelerates and de-risks progression of novel drug candidates from biosynthetic route and production host selection through optimized genetic design, strain/cell line development, bioprocessing, and production of materials for preclinical and first-in-human clinical trials.

7inABLE® Enabling Technology Licensing
CategoryTechnology Licensing
Description

Licensed proprietary suite of gene expression and DNA recombination tools used for developing enabling technologies, including capabilities for cyclic peptide production, DNA assembly, and synthetic biology applications, licensed to third parties such as Syngenta for crop protection.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Ab Biotechnology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Strategic relationship with Ab Biotechnology, a MHRA-licensed GMP facilities provider, to support development and GMP manufacturing of innovative biotechnology products. Located in close proximity, enabling integrated service delivery.

ingenza.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-02
Description

Partnership with Oxford-based biotech company HydRegen to develop a more sustainable method for manufacturing amine-based chemicals, eliminating heavy metal catalysts. Ingenza helped improve expression levels of a new candidate biocatalyst (Bio2Amine), increasing process efficiency and resource use. Resulted in much greater improvement in enzyme expression levels in a short period.

3Cellugy
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-22
Description

Collaboration with Denmark-based Cellugy to accelerate development of its platform for producing biofabricated cellulose. Focus on implementing techniques to identify key factors influencing cellulose production pathway and improving yield and productivity.

ingenza.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-03-20
Description

Strategic partnership with Opvia as QMS (Quality Management Systems) provider. Opvia's eQMS solution centralizes and manages Ingenza's quality management practices for process development and biomanufacturing operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-18
Description

Long-standing partnership (since 2017) with Phibro Ethanol, a division of Phibro Animal Health Corporation, to engineer novel yeast strains that increase bioethanol yield under challenging and conventional conditions. Key strategic customer and partner.

6Lucite International
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-26
Description

10-year collaboration with Lucite International (world's largest MMA producer, part of Mitsubishi Chemical) to develop biological manufacturing routes for methyl-methacrylate (MMA) with lower carbon footprints. Partners with universities of St Andrews, Strathclyde, Aberdeen, and Nottingham on related projects.

ingenza.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with University of Oxford on pan-sarbecovirus 'mosaic-8' vaccine program alongside Caltech, CPI, and CEPI. Also involved in subunit-vaccine development work with Professor Emeritus Alain Townsend. Oxford partnership dates back to COVID-19 vaccine development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Caltech on next-generation coronavirus vaccine (mosaic-8) development. Caltech and Oxford developed initial nanoparticle vaccine; Ingenza provides scalable manufacturing platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration alongside Caltech and Oxford on COVID-19 vaccine technology development and manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with University of Plymouth spin-out Amprologix for development and scale-up of epidermicin NI01 antibiotic. Ingenza holds a stake in Amprologix and provides biologics manufacturing platform. Project received £1.2M Innovate UK funding.

11Mitsubishi Chemical Corporation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

'Unleashing Putida' project to develop Pseudomonas putida as host for biobased methyl methacrylate production. Collaboration with Mitsubishi Chemical Corporation (Japan) and Mitsubishi Chemical Methacrylates (UK).

ingenza.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation study for ester-impregnated pH strips in 10 NHS hospitals. Imperial College London conducted modelling showing potential to avoid 132 unnecessary X-rays per 1,000 patients, saving £4,034 per 1,000 patients.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Syngenta exercised commercial licensing option for enabling technology using inABLE® suite for development of innovative crop protection products.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European CDMO specializing in microbial (E. coli, Pichia) expression for biologics and ATMPs. Closely comparable mid-sized peer with similar multi-host protein production capabilities as Ingenza.

TypeDirect peer
Description

Engineering biology company using AI/ML-driven enzyme engineering for pharmaceutical and sustainable chemicals applications. Comparable to Ingenza's biocatalysis and small-molecule development expertise, with similar focus on protein optimization.

TypeDirect peer
Description

CDMO specializing in microbial and mammalian biologics manufacturing, including E. coli, yeast (Pichia), and CHO expression systems. Closely comparable to Ingenza in offering multi-host process development and GMP manufacturing for clinical-stage biologics.

TypeBroad incumbent
Description

Global leader in biologics CDMO services offering mammalian and microbial expression, process development, and GMP manufacturing across all clinical phases. Directly competes with Ingenza in protein-based biologics, but operates at vastly larger scale with multi-site global capacity.

TypeEmerging player
Description

Synthetic biology platform combining engineering biology with AI/ML for strain engineering and biomanufacturing. Comparable to Ingenza's codABLE™ and inABLE® technology approaches for cell programming and protein production, though broader in scope.

6Cobra Biologics (Charles River)
TypeDirect peer
Description

Specialist CDMO offering microbial (E. coli) and mammalian expression, viral vector, and cell therapy services from UK facilities. Comparable mid-sized peer for Ingenza's biologics and gene therapy process development work.

TypeDirect peer
Description

US-based CDMO offering microbial and mammalian biologics process development and cGMP manufacturing. Directly comparable peer for Ingenza's mid-scale clinical biologics manufacturing capabilities.

TypeBroad incumbent
Description

One of the largest biologics CDMOs globally, providing end-to-end discovery, development, and manufacturing services. Overlaps with Ingenza's biologics development and manufacturing offerings but at much larger scale, particularly in mammalian cell culture.

TypeBroad incumbent
Description

Large-scale biologics CDMO offering mammalian cell line development, process development, and cGMP manufacturing. Competes with Ingenza for mammalian-based biologics programs but operates from mega-scale Korean facilities.

TypeBroad incumbent
Description

Global CDMO and contract testing services spanning biologics, small molecules, and analytical services. Competes with Ingenza in contract process development and analytical services across multiple therapeutic modalities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ingenza

Biopharmaceutical Contract Research Development and Manufacturing (CRDMO)ingenza.com

Ingenza firmographics

Firmographics
Name
Ingenza
Legal name
Ingenza Limited
Website
https://ingenza.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Ingenza industry classification

Industry
Product category
Biopharmaceutical Contract Research Development and Manufacturing (CRDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Biologics contract manufacturing
  • Strain engineering services
  • Protein therapeutics development
  • Biocatalysis small molecules
  • Sustainable bioprocess development

Where Ingenza is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ingenza business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Contract Research and Manufacturing Services: As a CRDMO, Ingenza provides fee-for-service preclinical and process development services through to first-in-human manufacturing. Revenue is generated through project-based contracts with pharmaceutical and biotech companies requiring protein production, strain development, and bioprocess optimization.
  2. Technology Licensing: Ingenza licenses its proprietary technologies (such as inABLE®) to third parties. Syngenta has exercised commercial licensing options for enabling technologies developed by Ingenza.
  3. Technology License Income (Bioethanol): Innovate UK grant funding supports commercialization of production technology targeting the bioethanol yeast market, with potential to generate substantial technology license income.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based custom engagements

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Ingenza product offering

Product offering

Core offering

Ingenza is a full-service protein Contract Research, Development and Manufacturing Organization (CRDMO) providing strain/cell line engineering, fermentation, process development, analytical development, and cGMP-ready material manufacturing for biologics, small molecule pharmaceuticals, and sustainable biotech applications. The company combines proprietary AI/ML tools (codABLE™) and its inGenius® CMC platform with multidisciplinary human expertise to deliver protein therapeutics and biocatalytic processes from discovery through first-in-human trials. It also licenses enabling technologies such as inABLE® to third parties and operates a multi-host production platform spanning E. coli, Bacillus subtilis, Pichia pastoris, and CHO cells.

Product overview

Ingenza operates as a protein Contract Research, Development and Manufacturing Organization (CRDMO) with a platform-plus-services architecture. The core inGenius® technology platform is enhanced by specialized AI/ML capabilities (codABLE™ for gene design optimization) and proprietary tools (inABLE® for DNA recombination). The service portfolio spans three main divisions—Biologics, Small Molecule, and Sustainable Biotech—each offering strain/cell line development, process development, analytical development, and material manufacturing. Specialized offerings include GenXpress Bacillus (an orthogonal protein production system), the inGenius® CMC platform for drug development, and diagnostic products like ester-impregnated pH strips. The company serves Human and Animal Health and Sustainable Technologies markets, combining AI tools with human expertise through a dual-engineering approach.

Differentiator

Problem solved

Functional benefit

Brands

  • inGenius®: Proprietary chemistry manufacturing and controls (CMC) platform that accelerates and de-risks progression of novel drug candidates from strain/cell line development through to first-in-human trials.
  • codABLE™
  • inABLE®
  • GenXpress Bacillus

Products and services

  • Biologics CRDMO Services Full-service biologics development including strain/cell line engineering, process development, analytical development, and cGMP material manufacturing, supporting drug discovery through preclinical evaluation and first-in-human studies for pharmaceutical and biotech clients.
  • Small Molecule CRDMO Services Engineering of efficient microbial production of natural products and biocatalytic regio- and enantio-selective synthesis of small molecule pharmaceuticals, chiral synthons, and advanced intermediates for pharmaceutical and chemical clients.
  • Sustainable Biotech CRDMO Services Deployment of sustainable bioprocesses for chemicals, enzymes, and custom solutions using diverse host organisms to achieve industrial performance, cost competitiveness, and Net Zero objectives for chemical, biofuel, and industrial biotech clients.
  • codABLE™ AI/ML Gene Design Platform AI/ML-driven gene design platform that uses machine learning to predict and tune recombinant protein expression by analyzing codon usage patterns, achieving predictive gene design for maximized production yields across E. coli, Bacillus subtilis, Pichia pastoris, and CHO hosts.
  • GenXpress Bacillus Protein Production System Orthogonal protein production system using engineered Bacillus host, providing performance comparable to E. coli expression systems and serving as a highly productive alternative for endotoxin-free biologics manufacturing.
  • inGenius® CMC Platform Chemistry Manufacturing and Controls platform that accelerates and de-risks progression of novel drug candidates from biosynthetic route and production host selection through optimized genetic design, strain/cell line development, bioprocessing, and production of materials for preclinical and first-in-human clinical trials.
  • inABLE® Enabling Technology Licensing Licensed proprietary suite of gene expression and DNA recombination tools used for developing enabling technologies, including capabilities for cyclic peptide production, DNA assembly, and synthetic biology applications, licensed to third parties such as Syngenta for crop protection.

Quantifiable outcome

  • 100% success rate producing customer targets
  • +5 more outcomes

Companies that use Ingenza

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Ingenza technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Ingenza partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Ab BiotechnologycoreStrategic or Co-development Partner · 16 April 2026Strategic relationship with Ab Biotechnology, a MHRA-licensed GMP facilities provider, to support development and GMP manufacturing of innovative biotechnology products. Located in close proximity, enabling integrated service delivery.
  • HydRegencoreStrategic or Co-development Partner · 2 December 2024Partnership with Oxford-based biotech company HydRegen to develop a more sustainable method for manufacturing amine-based chemicals, eliminating heavy metal catalysts. Ingenza helped improve expression levels of a new candidate biocatalyst (Bio2Amine), increasing process efficiency and resource use. Resulted in much greater improvement in enzyme expression levels in a short period.
  • CellugyminorStrategic or Co-development Partner · 22 August 2024Collaboration with Denmark-based Cellugy to accelerate development of its platform for producing biofabricated cellulose. Focus on implementing techniques to identify key factors influencing cellulose production pathway and improving yield and productivity.
  • OpviaminorImplementation/ SI/ Consulting Partner · 20 March 2024Strategic partnership with Opvia as QMS (Quality Management Systems) provider. Opvia's eQMS solution centralizes and manages Ingenza's quality management practices for process development and biomanufacturing operations.
  • Phibro EthanolcoreStrategic or Co-development Partner · 18 October 2023Long-standing partnership (since 2017) with Phibro Ethanol, a division of Phibro Animal Health Corporation, to engineer novel yeast strains that increase bioethanol yield under challenging and conventional conditions. Key strategic customer and partner.
  • Lucite InternationalcoreStrategic or Co-development Partner · 26 January 202110-year collaboration with Lucite International (world's largest MMA producer, part of Mitsubishi Chemical) to develop biological manufacturing routes for methyl-methacrylate (MMA) with lower carbon footprints. Partners with universities of St Andrews, Strathclyde, Aberdeen, and Nottingham on related projects.
  • University of OxfordcoreStrategic or Co-development PartnerCollaboration with University of Oxford on pan-sarbecovirus 'mosaic-8' vaccine program alongside Caltech, CPI, and CEPI. Also involved in subunit-vaccine development work with Professor Emeritus Alain Townsend. Oxford partnership dates back to COVID-19 vaccine development.
  • California Institute of Technology (Caltech)coreStrategic or Co-development PartnerPartnership with Caltech on next-generation coronavirus vaccine (mosaic-8) development. Caltech and Oxford developed initial nanoparticle vaccine; Ingenza provides scalable manufacturing platform.
  • Centre for Process Innovation (CPI)coreStrategic or Co-development PartnerCollaboration alongside Caltech and Oxford on COVID-19 vaccine technology development and manufacturing.
  • AmprologixcoreStrategic or Co-development PartnerPartnership with University of Plymouth spin-out Amprologix for development and scale-up of epidermicin NI01 antibiotic. Ingenza holds a stake in Amprologix and provides biologics manufacturing platform. Project received £1.2M Innovate UK funding.
  • Mitsubishi Chemical CorporationcoreStrategic or Co-development Partner'Unleashing Putida' project to develop Pseudomonas putida as host for biobased methyl methacrylate production. Collaboration with Mitsubishi Chemical Corporation (Japan) and Mitsubishi Chemical Methacrylates (UK).
  • Imperial College LondoncoreStrategic or Co-development PartnerClinical validation study for ester-impregnated pH strips in 10 NHS hospitals. Imperial College London conducted modelling showing potential to avoid 132 unnecessary X-rays per 1,000 patients, saving £4,034 per 1,000 patients.
  • SyngentacoreOEM/ Whitelabel/ Licensing PartnerSyngenta exercised commercial licensing option for enabling technology using inABLE® suite for development of innovative crop protection products.

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Ingenza competitors and assessment

Company assessment

Direct peers

  • Biovian: European CDMO specializing in microbial (E. coli, Pichia) expression for biologics and ATMPs. Closely comparable mid-sized peer with similar multi-host protein production capabilities as Ingenza.
  • Codexis: Engineering biology company using AI/ML-driven enzyme engineering for pharmaceutical and sustainable chemicals applications. Comparable to Ingenza's biocatalysis and small-molecule development expertise, with similar focus on protein optimization.
  • AGC Biologics: CDMO specializing in microbial and mammalian biologics manufacturing, including E. coli, yeast (Pichia), and CHO expression systems. Closely comparable to Ingenza in offering multi-host process development and GMP manufacturing for clinical-stage biologics.
  • Cobra Biologics (Charles River): Specialist CDMO offering microbial (E. coli) and mammalian expression, viral vector, and cell therapy services from UK facilities. Comparable mid-sized peer for Ingenza's biologics and gene therapy process development work.
  • Cytovance Biologics: US-based CDMO offering microbial and mammalian biologics process development and cGMP manufacturing. Directly comparable peer for Ingenza's mid-scale clinical biologics manufacturing capabilities.

Broad incumbents

  • Lonza: Global leader in biologics CDMO services offering mammalian and microbial expression, process development, and GMP manufacturing across all clinical phases. Directly competes with Ingenza in protein-based biologics, but operates at vastly larger scale with multi-site global capacity.
  • WuXi Biologics: One of the largest biologics CDMOs globally, providing end-to-end discovery, development, and manufacturing services. Overlaps with Ingenza's biologics development and manufacturing offerings but at much larger scale, particularly in mammalian cell culture.
  • Samsung Biologics: Large-scale biologics CDMO offering mammalian cell line development, process development, and cGMP manufacturing. Competes with Ingenza for mammalian-based biologics programs but operates from mega-scale Korean facilities.
  • Eurofins CDMO: Global CDMO and contract testing services spanning biologics, small molecules, and analytical services. Competes with Ingenza in contract process development and analytical services across multiple therapeutic modalities.

Emerging players

  • Ginkgo Bioworks: Synthetic biology platform combining engineering biology with AI/ML for strain engineering and biomanufacturing. Comparable to Ingenza's codABLE™ and inABLE® technology approaches for cell programming and protein production, though broader in scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Ingenza social profiles

Digital presence

Ingenza compliance and trust

Trust signal

Compliance1 record

Ingenza financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ingenza leadership team

Management profile

Number of profiles

Profiles17 records

Ingenza funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ingenza M&A and investment

M&A and investment

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ingenza

What does Ingenza do?

Ingenza is a full-service protein Contract Research, Development and Manufacturing Organization (CRDMO) providing strain/cell line engineering, fermentation, process development, analytical development, and cGMP-ready material manufacturing for biologics, small molecule pharmaceuticals, and sustainable biotech applications. The company combines proprietary AI/ML tools (codABLE™) and its inGenius® CMC platform with multidisciplinary human expertise to deliver protein therapeutics and biocatalytic processes from discovery through first-in-human trials. It also licenses enabling technologies such as inABLE® to third parties and operates a multi-host production platform spanning E. coli, Bacillus subtilis, Pichia pastoris, and CHO cells.

Is Ingenza a public or private company?

Ingenza is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ingenza founded?

Ingenza was founded in 2003. It employs 11 to 50 people.

Where is Ingenza based?

Ingenza is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Ingenza make money?

Three revenue lines are on record. Contract Research and Manufacturing Services are the primary driver. The others are technology Licensing and technology License Income (Bioethanol).

Who are Ingenza's main competitors?

Direct peers on record are Biovian, Codexis, AGC Biologics, Cobra Biologics (Charles River) and Cytovance Biologics. Broad incumbents are Lonza, WuXi Biologics, Samsung Biologics and Eurofins CDMO. Ginkgo Bioworks is listed as an emerging player.

Does Ingenza have an API?

No public API is recorded for Ingenza.

What industry is Ingenza in?

Ingenza's product category is Biopharmaceutical Contract Research Development and Manufacturing (CRDMO). Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaThe Future of Biotech OutsourcingNick Challoner, CEO of CRDMO Ingenza, discussed in a Q&A the company's strategic focus on protein therapeutics and its dual-engineering approach combining AI tools with human expertise to accelerate bioprocess development. He outlined Ingenza's 2030 vision to become the leading protein CRDMO across Human and Animal Health and Sustainable Technologies markets, targeting a protein therapeutics market valued at approximately $300 billion growing at 10% CAGR. The interview highlighted how CRDMOs are increasingly expected to reduce development time and risk for pharmaceutical innovators amid accelerating biopharmaceutical innovation.News-MedicalIngenza announces partnership with Cellugy to investigate the potential of biofabricated celluloseIngenza announced a partnership with Cellugy to accelerate development of a biofabricated cellulose platform. The collaboration aims to improve bacterial cellulose production, targeting personal care applications as a sustainable alternative to petrochemicals.News-MedicalIngenza announces partnership with Cellugy to investigate the potential of biofabricated celluloseIngenza announced a partnership with Cellugy to accelerate development of a biofabricated cellulose platform. The collaboration aims to improve bacterial cellulose production and yield, targeting personal care applications as a sustainable alternative to petrochemicals.News-MedicalIngenza and Phibro Ethanol accelerate the green fuel transitionIngenza and Phibro Ethanol partnered to develop KinetX yeast, a thermotolerant strain that secretes glucoamylase during fermentation, reducing enzyme addition and improving yield. The strain was created using Ingenza's adaptive laboratory evolution platforms. Additional yeast lines will debut internationally to further boost bioethanol production.News-MedicalIngenza appoints Steve Jones as its new Chief Financial OfficerIngenza appointed Steve Jones as Chief Financial Officer, effective immediately. He brings over 25 years of finance experience, including as finance director of a private pathology laboratory during the COVID-19 pandemic. The appointment aims to support the company's growth strategy.News-MedicalIngenza appoints new Strategic Business AdvisorIngenza appointed Dr Mark Chadwick as Strategic Business Advisor, bringing expertise from roles at BioFocus, Excelsyn, and Arcinova. He holds a PhD in Molecular Biology and an MBA, and will support the company's new business development strategy and collaborator network.News-MedicalIngenza collaborates with Amplifica to advance novel alopecia treatmentsIngenza and Amplifica are collaborating to develop a treatment for androgenic alopecia using Amplifica's signalling molecules that stimulate dormant hair follicle stem cells. The partnership will advance the molecules from proof of concept through toxicology and clinical trials, leveraging Ingenza's microbial and mammalian-cell line development capabilities.NatureGoing digital pays dividends for busy labsIngenza, a UK biotech firm, adopted the SciNote electronic lab notebook after a four-month trial to improve collaboration and quality management. The platform provides audit trails, automated reporting, and integrated data access, helping the company minimize errors and support technology transfer. The article highlights that such digital tools can pay for themselves many times over.News-MedicalIngenza collaborates with Johnson Matthey for efficient industrial enzyme synthesisIngenza and Johnson Matthey concluded a six-month project developing efficient enzyme production methods, including cytochrome P450. They used microbial hosts, a codon modification algorithm, and automated screening to increase expression. Both companies expressed satisfaction and look forward to continued collaboration.News-MedicalNew spinout company to tackle drug-resistant infections with novel antibioticsA University of Plymouth spinout company, Amprologix, was launched to develop and commercialize new antibiotics, including epidermicin, to combat drug-resistant infections. A UK government review estimates drug-resistant infections will cause 10 million deaths annually by 2050, and the company has secured a partnership with Ingenza.